Inflammatory Bowel Disease News and Research RSS Feed - Inflammatory Bowel Disease News and Research

Inflammatory bowel disease (IBD) is an ongoing or chronic health problem that causes inflammation and swelling in the digestive tract. The irritation causes bleeding sores called ulcers to form along the digestive tract. This in turn can cause crampy, abdominal pain and severe bloody diarrhea.

There are two main types of inflammatory bowel disease: ulcerative colitis (UC) and Crohn's disease (CD). The diseases are very similar. In fact, doctors often have a hard time figuring out which type of IBD a person has. The main difference between UC and CD is the area of the digestive tract they affect. CD can occur along the entire digestive tract and spread deep into the bowel wall. In contrast, UC usually only affects the top layer of the large intestine (colon) and rectum. Medicine can control the symptoms of IBD in most women. But for people who have severe IBD, surgery is sometimes needed. Over the course of a person's life, the symptoms of IBD often come and go. With close monitoring and medicines, most people with IBD lead full and active lives.
Steroid use associated with five-fold increase of blood clots in IBD patients

Steroid use associated with five-fold increase of blood clots in IBD patients

Compared with biologic therapy, corticosteroid (steroid) use is associated with a nearly five-fold increase of venous thromboembolism in inflammatory bowel disease (IBD) patients, according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. [More]

TxCell receives milestone payment of EUR 1 million concerning Ovasave collaboration, license agreement from Trizell

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today the receipt of the latest milestone payment of EUR 1 million from the Ovasave collaboration option, development and license agreement from Trizell (Trizell Holding SA). [More]
New study links inflammatory bowel diseases to increase in diversity of viruses

New study links inflammatory bowel diseases to increase in diversity of viruses

Inflammatory bowel diseases are associated with a decrease in the diversity of bacteria in the gut, but a new study led by researchers at Washington University School of Medicine in St. Louis has linked the same illnesses to an increase in the diversity of viruses. [More]
Findings may lead to novel therapeutic approaches to prevent fibrosis in Crohn's disease patients

Findings may lead to novel therapeutic approaches to prevent fibrosis in Crohn's disease patients

A natural protein made by immune cells may limit fibrosis and scarring in colitis, according to research published in the inaugural issue of Cellular and Molecular Gastroenterology and Hepatology, the new basic science journal of the American Gastroenterological Association. [More]
British scientists take major initiative to tackle Crohn's disease

British scientists take major initiative to tackle Crohn's disease

British scientists are playing a key role in a global quest to find the causes of an incurable bowel condition. [More]
Helsinn, Pharmacosmos sign license agreement for commercialization of Monofer in the US

Helsinn, Pharmacosmos sign license agreement for commercialization of Monofer in the US

Helsinn Group and Pharmacosmos A/S today jointly announce that they have entered into an agreement for the exclusive US commercialization rights to Monofer, an innovative intravenous iron replacement therapy under development for the treatment of Iron Deficiency Anemia. [More]
TxCell announces further enhancement to development of Ovasave for IBD treatment

TxCell announces further enhancement to development of Ovasave for IBD treatment

Paulsen Foundation to provide specialist management and scientific and development expertise that is dedicated to advanced therapies, i.e. cellular and gene therapies. This new class of highly promising biological therapies includes TxCell’s Ovasave. [More]
New study shows that people may inherit intestinal bacteria that cause inflammatory bowel disease

New study shows that people may inherit intestinal bacteria that cause inflammatory bowel disease

A new study by an international team of researchers shows for the first time that people may inherit some of the intestinal bacteria that cause Crohn's disease and ulcerative colitis, collectively know as inflammatory bowel disease (IBD). The study, recently published in Genome Medicine, also confirmed that antibiotics could worsen the imbalance in the gut microbes. [More]
Researchers remake brain and gut stem cells to study potential therapies for fatal diseases

Researchers remake brain and gut stem cells to study potential therapies for fatal diseases

Research scientists have developed a novel method to re-create brain and intestinal stem cells from patients who died decades ago, using DNA from stored blood samples to study the potential causes of debilitating illnesses such as inflammatory bowel disease. [More]
Automated biospecimen thawing: an interview with Dr Rolf Ehrhardt, CEO of BioCision

Automated biospecimen thawing: an interview with Dr Rolf Ehrhardt, CEO of BioCision

Surprisingly, even with decades of cryopreservation research, little progress has been made in the way frozen biospecimens are thawed. It’s still very common for researchers and clinicians to thaw cells and other frozen biological samples in a variety of manual ways ... [More]

Enterome, AbbVie to develop novel diagnostic products, therapies for microbiome-related diseases

ENTEROME Bioscience SA, a pioneer in the development of therapeutic solutions (drugs and diagnostics) based on a thorough understanding of the gut microbiome, announces that it has entered into a collaborative development agreement with AbbVie. [More]
Study points to major role of obesity in triggering, prolonging autoimmune diseases

Study points to major role of obesity in triggering, prolonging autoimmune diseases

Autoimmune diseases like Crohn's Disease and multiple sclerosis, in which the immune system attacks its own body rather than predatory invaders, affect 5-20% of the global community. A study published recently in Autoimmunity Reviews by Prof. Yehuda Shoenfeld, the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases at Tel Aviv University's Sackler Faculty of Medicine and Head of Zabludowicz Center for Autoimmune Diseases at Chaim Sheba Medical Center, Tel Hashomer, points to the major role obesity plays in triggering and prolonging these autoimmune diseases. [More]
Health benefits of modified formulation of curcumin supplements

Health benefits of modified formulation of curcumin supplements

The health benefits of over-the-counter curcumin supplements might not get past your gut, but new research shows that a modified formulation of the spice releases its anti-inflammatory goodness throughout the body. [More]
BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

BRI receives JDRF grant to explore why people with type 1 diabetes continue to produce insulin

Scientists at Benaroya Research Institute at Virginia Mason are studying a critical question in type 1 diabetes: Why do some people who get type 1 diabetes continue to produce small amounts of insulin over time while others stop? Researchers have found at the time of diagnosis with type 1 diabetes that many people continue to produce small amounts of insulin. [More]
TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

TxCell demonstrates therapeutic potential of Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, economically viable, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that TxCell researchers have achieved positive results for Col-Treg, its second product candidate from its ASTrIA platform, in a model of autoimmune uveitis, a leading cause of blindness with very limited treatment options. [More]
RPC1063 drug candidate has potential to improve treatment for ulcerative colitis patients

RPC1063 drug candidate has potential to improve treatment for ulcerative colitis patients

Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute. [More]
Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

GEP-NETs stands for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). This is a type of rare cancer that is increasing in incidence and prevalence – more on this later. [More]

TxCell to provide overview of T cellular therapy at 7th National Bio-Therapy Conference

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present on T cellular therapy for autoimmune diseases at the 7th National Bio-Therapy Conference, October 24-26, 2014 at Great Tang Hotel, Shanghai, China. [More]
New research shows impact of ulcerative colitis on patients' quality of life, treatment satisfaction

New research shows impact of ulcerative colitis on patients' quality of life, treatment satisfaction

New research shows that the majority of patients with the challenging inflammatory bowel disease, ulcerative colitis (UC), state that the three biggest impacts of the disease on their lives are on their emotional state (in terms of depression, anger or anxiety levels) (76%), ability to get adequate rest/sleep (75%), and taking sick days off work (70%). Those who have had a colectomy (removal of the colon) were more likely to suffer from these impacts. [More]
Kenneth Rainin Foundation grants $2.2 million for Inflammatory Bowel Disease research

Kenneth Rainin Foundation grants $2.2 million for Inflammatory Bowel Disease research

The Kenneth Rainin Foundation announced today that it will grant $2.2 million to scientists to conduct Inflammatory Bowel Disease (IBD) research. The Rainin Foundation offers support for cutting-edge projects that typically are not eligible for funding from more traditional sources due to their ground-breaking, pioneering nature. [More]